2022
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang Z, Peng L, Filler R, Suzuki K, McNamara A, Lin Q, Renauer PA, Yang L, Menasche B, Sanchez A, Ren P, Xiong Q, Strine M, Clark P, Lin C, Ko AI, Grubaugh ND, Wilen CB, Chen S. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. Nature Communications 2022, 13: 3250. PMID: 35668119, PMCID: PMC9169595, DOI: 10.1038/s41467-022-30878-4.Peer-Reviewed Original ResearchConceptsHeterologous boosterSARS-CoV-2Antibody responseMRNA vaccinesMRNA vaccinationDelta variantOmicron variantType of vaccinationStrong antibody responseMRNA vaccine candidatesVaccine candidatesNeutralization potencyImmune evasionSARS-CoV.Two weeksComparable titersVaccinationVaccineTiters 10MiceOmicronWeeksWA-1LNP-mRNABooster
2021
A live attenuated-vaccine model confers cross-protective immunity against different species of the Leptospira genus
Wunder EA, Adhikarla H, Hamond C, Bonner K, Liang L, Rodrigues CB, Bisht V, Nally JE, Alt DP, Reis MG, Diggle PJ, Felgner PL, Ko A. A live attenuated-vaccine model confers cross-protective immunity against different species of the Leptospira genus. ELife 2021, 10: e64166. PMID: 33496263, PMCID: PMC7837694, DOI: 10.7554/elife.64166.Peer-Reviewed Original ResearchConceptsCross-protective immunityPathogenic Leptospira speciesTerms of morbidityLeptospira speciesTransient bacteremiaSingle doseAntibody responseImmune responseApplicable vaccinesVaccine candidatesAnimal modelsEffective preventionAttenuated mutantsZoonotic diseaseLeptospira genusPotential correlatesDisease transmissionDiseaseLeptospirosisImmunityBacteremiaMorbidityImmunizationVaccineRelevant proteins